2026-04-27T07:54:47Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/181402024-02-12T19:47:43Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16927

00925njm 22002777a 4500 dc Cismaru, Anca Liliana author Rudin, Deborah author Ibañez, Luisa author Liakoni, Evangelia author Bonadies, Nicolas author Kreutz, Reinhold author Carvajal, Alfonso author Lucena, Maria Isabel author Martin, Javier author Sancho Ponce, Esther author Molokhia, Mariam author Eriksson, Niclas author EuDAC Collaborators, author Krähenbühl, Stephan author Largiadèr, Carlo R author Haschke, Manuel author Hallberg, Pär author Wadelius, Mia author Amstutz, Ursula author 2020-10-29 Agranulocytosis is a rare yet severe idiosyncratic adverse drug reaction to metamizole, an analgesic widely used in countries such as Switzerland and Germany. Notably, an underlying mechanism has not yet been fully elucidated and no predictive factors are known to identify at-risk patients. With the aim to identify genetic susceptibility variants to metamizole-induced agranulocytosis (MIA) and neutropenia (MIN), we conducted a retrospective multi-center collaboration including cases and controls from three European populations. Association analyses were performed using genome-wide genotyping data from a Swiss cohort (45 cases, 191 controls) followed by replication in two independent European cohorts (41 cases, 273 controls) and a joint discovery meta-analysis. No genome-wide significant associations (p http://hdl.handle.net/10668/16529 http://hdl.handle.net/20.500.12105/18140 33138277 10.3390/genes11111275 2073-4425 Genes Dipyrone Drug-induced agranulocytosis Genome-wide association study Metamizole Pharmacogenetics Genome-Wide Association Study of Metamizole-Induced Agranulocytosis in European Populations.